Lite Strategy, Inc. (LITS)

1.14 +0.10 (+9.62%) USD  |  NASDAQ  |  Sep 04, 16:00
1.14 0.00 (0.00%) After-Hours: 20:00
More

Lite Strategy SG&A Expense (TTM) : 11.93M for March 31, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for LITS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2002. Start Trial.
Date Value
March 31, 2026 11.93M
December 31, 2025 11.60M
September 30, 2025 11.44M
June 30, 2025 13.53M
March 31, 2025 14.87M
December 31, 2024 17.08M
September 30, 2024 21.95M
June 30, 2024 23.30M
March 31, 2024 29.12M
December 31, 2023 31.70M
September 30, 2023 32.18M
June 30, 2023 33.13M
March 31, 2023 28.93M
December 31, 2022 30.69M
September 30, 2022 30.12M
June 30, 2022 30.54M
March 31, 2022 31.40M
December 31, 2021 28.68M
September 30, 2021 26.41M
June 30, 2021 24.41M
March 31, 2021 22.31M
December 31, 2020 19.96M
September 30, 2020 18.50M
June 30, 2020 16.72M
March 31, 2020 15.93M
Date Value
December 31, 2019 15.70M
September 30, 2019 15.33M
June 30, 2019 14.60M
March 31, 2019 13.31M
December 31, 2018 12.16M
September 30, 2018 10.70M
June 30, 2018 9.787M
March 31, 2018 9.158M
December 31, 2017 8.824M
September 30, 2017 8.436M
June 30, 2017 8.628M
March 31, 2017 8.638M
December 31, 2016 8.476M
September 30, 2016 8.451M
June 30, 2016 7.601M
March 31, 2016 7.674M
December 31, 2015 7.869M
September 30, 2015 8.339M
June 30, 2015 8.948M
March 31, 2015 9.185M
December 31, 2014 8.991M
September 30, 2014 8.525M
June 30, 2014 7.897M
March 31, 2014 7.332M
December 31, 2013 6.566M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. 14.87M
ACADIA Pharmaceuticals, Inc. 620.29M
Alnylam Pharmaceuticals, Inc. 1.318B
Anika Therapeutics, Inc. 52.67M
Savara, Inc. 56.71M